大摩：予药明生物“增持”评级目标价升3.6%至170港元_老虎社区_美港股上老虎

大摩：予药明生物“增持”评级目标价升3.6%至170港元

智通财经2021-08-26

　　大摩发布研究报告称，予药明生物(02269)“增持”评级，目标价自164港元上调至170港元，上调2021-24年间盈测1%至9%，以反映强劲上半年业绩表现，收入及毛利润预测也同步上调。

关注同花顺财经（ths518），获取更多机会

责任编辑：cjh

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

记事本2020
·2021-08-26
666
回复
点赞
举报

热议股票

7x24

全部

{"i18n":{"language":"zh_CN"},"data":{"share":"https://www.laohu8.com/m/news/2162106440?lang=zh_CN&edition=full","thumbnail":"https://static.tigerbbs.com/24fa8350588843d92f819ac12ab5ce16","is_english":false,"pubTime":"2021-08-26 14:37","share_image_url":"https://static.laohu8.com/f0343184bd9b9c963ed02b302442e2b8","id":"2162106440","market":"sh","top_or_hot":-1,"title":"大摩：予药明生物“增持”评级 目标价升3.6%至170港元","media":"智通财经","content":"<html><body><div>\n<p>　　大摩发布研究报告称，予<a href=\"https://laohu8.com/S/02269\">药明生物</a>(02269)“增持”评级，目标价自164港元上调至170港元，上调2021-24年间盈测1%至9%，以反映强劲上半年业绩表现，收入及毛利润预测也同步上调。</p>\n<p><strong>关注<a href=\"https://laohu8.com/S/300033\">同花顺</a>财经（ths518），获取更多机会</strong></p>\n<span></span>\n<div><span>责任编辑：cjh</span></div>\n</div></body></html>","source":"tonghuashun","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>大摩：予药明生物“增持”评级 目标价升3.6%至170港元</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n大摩：予药明生物“增持”评级 目标价升3.6%至170港元\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-26 14:37 北京时间&nbsp;&nbsp;&nbsp;<a href=http://stock.10jqka.com.cn/hks/20210826/c632175865.shtml><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>大摩发布研究报告称，予药明生物(02269)“增持”评级，目标价自164港元上调至170港元，上调2021-24年间盈测1%至9%，以反映强劲上半年业绩表现，收入及毛利润预测也同步上调。\n关注同花顺财经（ths518），获取更多机会\n\n责任编辑：cjh</p>\n\n<a href=\"http://stock.10jqka.com.cn/hks/20210826/c632175865.shtml\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02269","symbol_name":"药明生物","start_time":0,"source_url":"http://stock.10jqka.com.cn/hks/20210826/c632175865.shtml","article_id":"2162106440","we_media_id":null,"thumbnails":["https://static.tigerbbs.com/24fa8350588843d92f819ac12ab5ce16"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2162106440","pubTimestamp":1629959831,"columns":[],"sourceInfo":{"source_id":"tonghuashun","name":"同花顺"},"weMediaInfo":null,"summary":"大摩发布研究报告称，予药明生物(02269)“增持”评级，目标价自164港元上调至170港元，上调2021-24年间盈测1%至9%，以反映强劲上半年业绩表现，收入及毛利润预测也同步上调。 ...","collect":0,"end_time":0,"defaultTopTitle":"10jqka.com.cn","property":["rate"],"viewcount":null,"language":"zh","relate_stocks":{"02269":"药明生物"},"translate_title":"Damo: The target price of WUXI BIO's \"overweight\" rating increased by 3.6% to HK $170","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02269":1},"content_text":"大摩发布研究报告称，予药明生物(02269)“增持”评级，目标价自164港元上调至170港元，上调2021-24年间盈测1%至9%，以反映强劲上半年业绩表现，收入及毛利润预测也同步上调。\n关注同花顺财经（ths518），获取更多机会\n\n责任编辑：cjh","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"},"commentList":[{"id":810814571,"gmtCreate":1629962150993,"gmtModify":1629962150993,"author":{"id":"3550828792714737","authorId":"3550828792714737","name":"记事本2020","avatar":"https://static.tigerbbs.com/f529f483c65820f1fbdbed82968cd4d7","vip":1,"crmLevel":5,"crmLevelSwitch":0,"idStr":"3550828792714737","authorIdStr":"3550828792714737"},"htmlText":"666","listText":"666","text":"666","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/810814571","repostId":2162106440,"repostType":2,"repost":{"id":"2162106440","kind":"news","pubTimestamp":1629959831,"share":"https://www.laohu8.com/m/news/2162106440?lang=&edition=full","pubTime":"2021-08-26 14:37","market":"sh","language":"zh","title":"大摩：予药明生物“增持”评级 目标价升3.6%至170港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2162106440","media":"智通财经","summary":"大摩发布研究报告称，予药明生物(02269)“增持”评级，目标价自164港元上调至170港元，上调2021-24年间盈测1%至9%，以反映强劲上半年业绩表现，收入及毛利润预测也同步上调。 ...","content":"<html><body><div>\n<p>　　大摩发布研究报告称，予<a href=\"https://laohu8.com/S/02269\">药明生物</a>(02269)“增持”评级，目标价自164港元上调至170港元，上调2021-24年间盈测1%至9%，以反映强劲上半年业绩表现，收入及毛利润预测也同步上调。</p>\n<p><strong>关注<a href=\"https://laohu8.com/S/300033\">同花顺</a>财经（ths518），获取更多机会</strong></p>\n<span></span>\n<div><span>责任编辑：cjh</span></div>\n</div></body></html>","source":"tonghuashun","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>大摩：予药明生物“增持”评级 目标价升3.6%至170港元</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n大摩：予药明生物“增持”评级 目标价升3.6%至170港元\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-26 14:37 北京时间&nbsp;&nbsp;&nbsp;<a href=http://stock.10jqka.com.cn/hks/20210826/c632175865.shtml><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>大摩发布研究报告称，予药明生物(02269)“增持”评级，目标价自164港元上调至170港元，上调2021-24年间盈测1%至9%，以反映强劲上半年业绩表现，收入及毛利润预测也同步上调。\n关注同花顺财经（ths518），获取更多机会\n\n责任编辑：cjh</p>\n\n<a href=\"http://stock.10jqka.com.cn/hks/20210826/c632175865.shtml\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/24fa8350588843d92f819ac12ab5ce16","relate_stocks":{"02269":"药明生物"},"source_url":"http://stock.10jqka.com.cn/hks/20210826/c632175865.shtml","is_english":false,"share_image_url":"https://static.laohu8.com/f0343184bd9b9c963ed02b302442e2b8","article_id":"2162106440","content_text":"大摩发布研究报告称，予药明生物(02269)“增持”评级，目标价自164港元上调至170港元，上调2021-24年间盈测1%至9%，以反映强劲上半年业绩表现，收入及毛利润预测也同步上调。\n关注同花顺财经（ths518），获取更多机会\n\n责任编辑：cjh","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":0,"commentSize":1,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}